Latest Ratios: P/E Ratio 17.1x · EV/EBITDA 13.4x · ROE 28.3%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $272M | $543M | $423M | $107M | $117M | $251M | $293M | $246M | $189M | $262M | $123M |
| Enterprise Value | $210M | $481M | $381M | $83M | $101M | $228M | $278M | $229M | $167M | $217M | $122M |
| P/E Ratio → | 17.10 | 31.80 | 48.27 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.10 | 4.20 | 4.25 | 1.28 | 1.63 | 3.73 | 4.95 | 5.31 | 5.98 | 12.37 | 5.70 |
| P/B Ratio | 3.82 | 7.10 | 9.18 | 3.77 | 4.09 | 7.92 | 17.85 | 12.03 | 6.94 | 4.87 | 12.38 |
| P/FCF | 20.72 | 41.34 | 35.44 | 15.39 | — | — | — | — | — | — | — |
| P/OCF | 20.27 | 40.44 | 34.96 | 15.07 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.72 | 3.83 | 1.00 | 1.40 | 3.38 | 4.70 | 4.95 | 5.28 | 10.25 | 5.65 |
| EV / EBITDA | 13.36 | 30.57 | 41.42 | — | — | — | — | — | — | — | — |
| EV / EBIT | 14.72 | 33.67 | 49.38 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 36.62 | 31.93 | 11.96 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.3% | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% | 55.7% | 50.9% | 49.4% | 48.0% |
| Operating Margin | 11.0% | 11.0% | 7.8% | -6.7% | -25.9% | -40.1% | -33.5% | -67.6% | -105.1% | -77.2% | -13.4% |
| Net Profit Margin | 13.4% | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% | -69.4% | -105.6% | -53.7% | -13.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 28.3% | 28.3% | 22.9% | -17.3% | -54.8% | -112.7% | -108.1% | -135.0% | -82.2% | -35.7% | -38.4% |
| ROA | 19.9% | 19.9% | 13.9% | -9.1% | -29.6% | -56.4% | -50.7% | -78.0% | -63.5% | -27.6% | -15.2% |
| ROIC | 114.1% | 114.1% | 131.7% | -48.8% | -132.7% | -407.2% | -582.1% | -544.4% | -354.8% | -137.4% | -30.7% |
| ROCE | 20.9% | 20.9% | 18.2% | -15.9% | -48.8% | -87.2% | -84.4% | -118.2% | -80.5% | -50.0% | -29.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.06 | 0.12 | 0.15 | 0.15 | 0.10 | 0.08 | 0.01 | 0.01 | 0.06 |
| Debt / EBITDA | 0.18 | 0.18 | 0.29 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.81 | -0.91 | -0.84 | -0.56 | -0.73 | -0.90 | -0.83 | -0.81 | -0.83 | -0.10 |
| Net Debt / EBITDA | -3.94 | -3.94 | -4.54 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -4.71 | -3.50 | -3.43 | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -492.24 | -279.63 | -36.95 | -419.90 | -107.04 | -7.81 |
Net cash position: cash ($65M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.86 | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 | 1.77 |
| Quick Ratio | 3.83 | 3.83 | 3.06 | 1.70 | 1.78 | 2.00 | 1.25 | 1.46 | 1.96 | 6.35 | 0.88 |
| Cash Ratio | 3.25 | 3.25 | 2.48 | 1.32 | 1.14 | 1.59 | 1.00 | 1.24 | 1.55 | 5.61 | 0.19 |
| Asset Turnover | — | 1.22 | 1.46 | 1.52 | 1.33 | 1.17 | 1.54 | 1.15 | 0.75 | 0.34 | 1.10 |
| Inventory Turnover | 2.26 | 2.26 | 4.14 | 2.26 | 1.99 | 1.91 | 2.05 | 1.78 | 1.88 | 1.85 | 1.42 |
| Days Sales Outstanding | — | 27.47 | 28.47 | 22.86 | 42.97 | 28.28 | 16.59 | 17.15 | 51.07 | 91.90 | 98.59 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.8% | 3.1% | 2.1% | — | — | — | — | — | — | — | — |
| FCF Yield | 4.8% | 2.4% | 2.8% | 6.5% | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $85M | $80M | $75M | $70M | $67M | $61M | $57M | $55M | $45M | $37M |
Regulatory and Patent Litigation
Based on reported figures, NAGE trades at a P/E of 17.10, which appears to bake in a growth premium that may be increasingly difficult to justify given the recent deceleration in top-line expansion observed in the most recent quarterly filings compared to historical performance.
The current valuation suggests investors are pricing in a sustained longevity-market tailwind, yet the lack of a clear PEG ratio indicates that the market may be struggling to reconcile the company's high-growth narrative with its recent operational volatility. Investors should monitor whether the forward P/E of 14.92 reflects a realistic assessment of future earnings or if the market is underestimating the potential for margin compression from ongoing legal and R&D expenditures.
As reported in financial statements, NAGE's ROIC has experienced a sharp decline from a peak of 115.3% in 2024Q4 to 7.2% in 2026Q1, indicating that the company's ability to generate high returns on its invested capital is currently under significant pressure.
This dramatic drop suggests that the capital deployed into the business is no longer yielding the outsized returns seen during the initial commercialization phase. The trend warrants further investigation into whether this decay is a temporary result of increased asset intensity or a structural shift in the profitability of the core NR molecule.
According to recent SEC filings, NAGE's cash conversion cycle has expanded to 112 days in 2026Q1, driven largely by an inventory turnover period of 174 days, which suggests that the company is struggling to efficiently convert its proprietary ingredient stock into realized cash flow.
The lengthening of the cash conversion cycle appears to be a primary driver of the company's recent free cash flow volatility. This inefficiency may indicate that the company is over-producing in anticipation of demand that has not yet materialized, potentially leading to future inventory obsolescence risks.
Based on reported figures, NAGE maintains a strong current ratio of 4.61, providing a substantial liquidity cushion that appears to insulate the firm from immediate solvency risks despite the recent deterioration in free cash flow margins to negative 4.0% in the most recent quarter.
While the balance sheet remains healthy, the high liquidity position may be misleading if it is primarily supported by equity raises rather than internally generated cash. Investors should monitor whether this liquidity is being deployed effectively to defend the patent moat or if it is merely serving as a buffer against persistent operational cash burn.
As noted in financial statements, the P/E ratio is a fundamentally flawed metric for NAGE, as it fails to account for the significant non-recurring legal expenses and stock-based compensation that frequently distort the company's reported net income and mask the true underlying cash-burn rate.
Analysts should instead focus on EV/EBITDA or adjusted free cash flow, which better capture the operational reality of an IP-heavy biotech-lite firm. Relying on P/E may lead to an overly optimistic view of the company's earning power, ignoring the substantial capital required to maintain its competitive position in the longevity market.
Includes 30+ ratios · 19 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NAGE stock.
Niagen Bioscience Inc's current P/E ratio is 17.1x. The historical average is 40.0x.
Niagen Bioscience Inc's current EV/EBITDA is 13.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 36.0x.
Niagen Bioscience Inc's return on equity (ROE) is 28.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -96.5%.
Based on historical data, Niagen Bioscience Inc is trading at a P/E of 17.1x. Compare with industry peers and growth rates for a complete picture.
Niagen Bioscience Inc has 64.3% gross margin and 11.0% operating margin. Operating margin between 10-20% is typical for established companies.
Niagen Bioscience Inc's Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.